Addendum
Asciminib (chronic myeloid leukaemia) – Addendum to Project A25-70
Report documents
-
Addendum
Asciminib (chronic myeloid leukaemia) – Addendum to Project A25-70
Dossier assessment
Indication:
Adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with ≥ 2 tyrosine kinase inhibitors
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
20-11-2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-129
- Commission
- Commission awarded on 07.10.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-129_en
Connected Projects
-
Dossier assessment
Asciminib (chronic myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed